Keyword: Tremfya (guselkumab)
Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.
Johnson & Johnson’s Tremfya may have debuted behind Novartis' Cosentyx, but it has now topped the blockbuster in a head-to-head trial.
Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.
Sun Pharma’s $80 million psoriasis licensing deal just paid off. But now, its new drug Ilumya will go up against established player J&J.
After a bruising two-day play-in, Taltz and Nerlyx are among the victors in our first round of this year’s drug name tournament challenge.
Tremfya, the next-gen psoriasis biologic from Johnson & Johnson, began airing its first DTC campaign two weeks ago, joining two close rivals on the tube.
Remicade had a tougher time against biosims in Q4 than it has in the past, but J&J's other immunology meds made big gains, the company said.
Recent years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class med may still be on its way, one analyst says.
Calling all digital entrepreneurs: Johnson & Johnson is looking for creative tech skincare solutions in its Digital Beauty QuickFire Challenge.